Citadel Advisors
PLX icon

Citadel Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Citadel Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.2K Buy
25,900
+8,900
+52% +$22.1K ﹤0.01% 12359
2025
Q4 		$30.6K Buy
+17,000
New +$34.8K ﹤0.01% 12220
2025
Q2 		– Sell
-39,000
Closed -$99.8K – 14492
2025
Q1 		$99.8K Sell
39,000
-1,900
-5% -$4.54K ﹤0.01% 11471
2024
Q4 		$76.9K Sell
40,900
-20,200
-33% -$28.6K ﹤0.01% 11834
2024
Q3 		$62.3K Buy
61,100
+6,000
+11% +$6.31K ﹤0.01% 11662
2024
Q2 		$64.5K Buy
55,100
+42,300
+330% +$50K ﹤0.01% 11476
2024
Q1 		$16.1K Sell
12,800
-66,900
-84% -$99.9K ﹤0.01% 13153
2023
Q4 		$142K Buy
79,700
+29,200
+58% +$45.4K ﹤0.01% 10469
2023
Q3 		$83.8K Sell
50,500
-84,000
-62% -$151K ﹤0.01% 11109
2023
Q2 		$269K Buy
134,500
+42,600
+46% +$101K ﹤0.01% 9276
2023
Q1 		$193K Buy
91,900
+40,700
+79% +$71.4K ﹤0.01% 10246
2022
Q4 		$70.1K Buy
51,200
+7,300
+17% +$8.01K ﹤0.01% 11700
2022
Q3 		$46K Sell
43,900
-6,300
-13% -$6.98K ﹤0.01% 11689
2022
Q2 		$55K Buy
50,200
+14,500
+41% +$17K ﹤0.01% 11871
2022
Q1 		$38K Buy
35,700
+2,600
+8% +$2.38K ﹤0.01% 12969
2021
Q4 		$28K Sell
33,100
-74,700
-69% -$78.2K ﹤0.01% 13496
2021
Q3 		$143K Sell
107,800
-12,700
-11% -$19.3K ﹤0.01% 12432
2021
Q2 		$230K Buy
120,500
+68,100
+130% +$234K ﹤0.01% 11857
2021
Q1 		$234K Buy
52,400
+28,300
+117% +$132K ﹤0.01% 11397
2020
Q4 		$87K Buy
24,100
+2,600
+12% +$9.32K ﹤0.01% 10301
2020
Q3 		$83K Buy
21,500
+9,800
+84% +$35.4K ﹤0.01% 9373
2020
Q2 		$44K Buy
+11,700
New +$40K ﹤0.01% 9358
2019
Q4 		– Sell
-1,770
Closed -$4K – 9598
2019
Q3 		$4K Sell
1,770
-30
-2% -$90 ﹤0.01% 9075
2019
Q2 		$8K Buy
+1,800
New +$7.61K ﹤0.01% 9055
2019
Q1 		– Sell
-4,330
Closed -$13K – 9725
2018
Q4 		$13K Buy
4,330
+2,510
+138% +$11.9K ﹤0.01% 8871
2018
Q3 		$13K Buy
+1,820
New +$9.14K ﹤0.01% 9084
2018
Q2 		– Sell
-1,340
Closed -$7K – 9171
2018
Q1 		$7K Buy
+1,340
New +$8.82K ﹤0.01% 8190
2017
Q4 		– Sell
-3,870
Closed -$22K – 8324
2017
Q3 		$22K Buy
3,870
+1,360
+54% +$8.71K ﹤0.01% 7340
2017
Q2 		$21K Buy
2,510
+620
+33% +$5.82K ﹤0.01% 7275
2017
Q1 		$26K Buy
+1,890
New +$17K ﹤0.01% 7197
2016
Q1 		– Sell
-200
Closed -$2K – 7691
2015
Q4 		$2K Sell
200
-680
-77% -$6.92K ﹤0.01% 8581
2015
Q3 		$10K Sell
880
-1,860
-68% -$29.6K ﹤0.01% 8470
2015
Q2 		$53K Buy
2,740
+2,630
+2,391% +$54.6K ﹤0.01% 7612
2015
Q1 		$2K Buy
110
+60
+120% +$1.18K ﹤0.01% 8416
2014
Q4 		$1K Sell
50
-730
-94% -$15.7K ﹤0.01% 8416
2014
Q3 		$19K Buy
780
+540
+225% +$15.6K ﹤0.01% 7482
2014
Q2 		$9K Buy
240
+50
+26% +$2.02K ﹤0.01% 7606
2014
Q1 		$9K Sell
190
-680
-78% -$31.7K ﹤0.01% 7542
2013
Q4 		$34K Buy
870
+10
+1% +$421 ﹤0.01% 6232
2013
Q3 		$39K Buy
860
+370
+76% +$19K ﹤0.01% 5920
2013
Q2 		$24K Buy
+490
New +$26K ﹤0.01% 5993

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Citadel Advisors's PLX Position: Q1 2026 in Review

Citadel Advisors sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 317,628 shares — an estimated $788K sold.

Citadel Advisors first reported a position in PLX in Q2 2013 and held it in 38 quarters. The position peaked at $572K in Q4 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Citadel Advisors reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 317,628 Protalix BioTherapeutics shares in Q1 2026, an estimated $788K.
  • Citadel Advisors first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 38 quarters.
  • Citadel Advisors's Protalix BioTherapeutics position peaked at $572K in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.